The looming threat of HIV/AIDS drug resistance in South Africa by Ncayiyana, Daniel J
In the February 2004 issue of the SAMJ, this column
commented approvingly on the 'Operational Plan for the
Comprehensive Treatment and Care for HIV and AIDS'
prepared by the Department of Health and approved by
Cabinet on 20 November 2003. The hard-fought and long
awaited rollout of antiretroviral treatment (ART) in the public
sector represents the promise of a better quality of life for 5
million South Africans living with HIV and AIDS, but there are
booby traps lurking in the way that could turn this bold
venture into a horrific nightmare, and one of these is the threat
of the development of widespread antiretroviral drug
resistance.
Antiretroviral drug resistance develops when susceptible
virus is selectively suppressed, creating space for drug-resistant
mutant strains to predominate. A mutation is essentially a
replication error, and because HIV replicates extraordinarily
rapidly (on average, 10 billion HIV particles are produced and
cleared everyday, with one new mutation introduced, on
average, in each new genome),1 mutations occur with great
ease and rapidity. Over time, these mutants become the
dominant strain.
Suboptimal adherence to ART promotes drug resistance by
reducing the ability to suppress the virus effectively, thus
accelerating the emergence of resistant strains. For this reason,
it has been asserted that 'taking no drug at all is likely to be
better than taking it erratically, with lapses in regular dosing
that leaves adherence less than 85%'.1
In the South African context, treatment adherence may prove
to be the Achilles' heel in the ART rollout for a whole host of
factors ranging from patient non-compliance to systemic
deficiencies in drug availability and monitoring capacity. As
noted in a previous editorial, the envisaged ART programme is
unique and without precedent in the world in terms of sheer
size and scope, and is destined to exert extraordinary pressures
on our health infrastructure. Our track record in the
implementation of mass health programmes is not great. South
Africa's mass treatment programme of tuberculosis, with an
overall cure rate well below the optimum as defined by the
WHO, speaks to the inadequacy of our health system
infrastructure to cope with campaigns of this magnitude.
In this regard, the warnings of Dr Peter Barron, Director of
the Initiative for Sub-District Support of the Health Systems
Trust, contained in a comprehensive address delivered at a
symposium at Wits University on the topic of scaling up ART,2
are worth quoting at some length. He cautions that 'the first
principle of medicine is "Do no harm". Our aim must not only
be to introduce antiretrovirals, but to make it work. If we do
not do so, the intervention could do more harm than good. I
believe that if we introduce an ART programme for these 5
million in the same way that we have approached the
introduction of the termination of pregnancy programme, the
cervical screening programme, the voluntary counselling and
testing programme, and the prevention of mother-to-child
transmission programme, then we will certainly do harm'. 
It is generally acknowledged that stronger health systems
are essential for effective HIV and AIDS prevention and care.3
Yet, inherent in the mass management of the HIV and AIDS
pandemic is the potential to weaken the very system needed to
contain the disease. It is therefore essential that the pandemic
not be managed so as to overwhelm the public sector health
system by overstretching its finite resources. Successful
implementation of the ART programme is not possible without
increasing investment in the system. Barron points out that
only about 15% of the total public sector health budget is
devoted to primary care, and that adding on an ART
programme 'without addressing the current under-funding will
exponentially increase the under-funding on primary care',
thus weakening the primary care system.
Drug resistance will be aggravated by jurisdictional resource
inequities whereby the worst-resourced health districts expend
R30 per capita as opposed to around R300 by the best-
resourced ones. Paradoxically, the districts with the poorest
infrastructure and the lowest resource provision have the
greatest social, economic and health problems. If the resource-
poor districts are selected to provide ART, the care will be
inadequate and substandard, and will breed drug resistance.
However, the single greatest risk facing the introduction of
an ART programme, according to Barron, is the shortage of
skilled personnel in the public heath sector, particularly in the
rural and disadvantaged urban areas, which also happen to be
the areas with the highest prevalence of HIV and AIDS. 'To
expect a huge ART programme to be run by already
overworked staff is wishful thinking and additional doctors,
nurses and other health care workers will have to be added to
the system.' Ironically, among the causes for the shortage are
morbidity and mortality among health care providers due to
HIV and AIDS.
In locations where ART has been successfully implemented
in developing countries such as Barbados, Brazil and Nigeria,
AIDS deaths have been halved, as have hospitalisation
duration and hospital occupancy rates for the disease.4 South
Africa can match these norms, but if antiretroviral drug
resistance is allowed to become a dominant factor, we will have
taken a huge step backwards. It is therefore imperative that the
ART rollout is implemented
with deliberate care, and that
the necessary investment is
made to strengthen the health
system infrastructure and to
achieve optimal staffing if the
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